Scribe Therapeutics Inc. announced that Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics. CRISPR by Design?, Scribe?s data-driven design and engineering approach for optimizing its CRISPR-based platforms and assets including X-Editing (XE) technologies, continues to drive forward a new era of truly transformative genetic medicines. Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology indications in 2022, followed by an expansion of the collaboration in 2023 to advance in vivo medicines for genomic diseases.